WilmerHale Advises Casdin Capital in $150M Series B Financing with MOMA Therapeutics

WilmerHale Advises Casdin Capital in $150M Series B Financing with MOMA Therapeutics

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
On May 10, 2022, MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines targeting the molecular machines that underlie human disease, announced the completion of a $150 million Series B financing. The financing was led by Goldman Sachs Asset Management, with participation from other new investors Section 32, Pavilion Capital, Invus and LifeSci Venture Partners. All of MOMA’s Series A investors, including Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Casdin Capital, Rock Springs Capital, Creacion Ventures, Alexandria Venture Investments and other undisclosed investors, also participated in the round.

The WilmerHale team advising Casdin Capital was led by Eric Hanson and included Nare Aleksanyan.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel